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Monoterpene indole alkaloids from Catharan-
thus roseus (Madagascar periwinkle), such as
the anticancer agents vinblastine and vincris-
tine, have important pharmacological activities.
Metabolic engineering of alkaloid biosynthesis
can provide an efficient and environmentally
friendly route to analogs of these synthetically
challenging and pharmaceutically valuable nat-
ural products. However, the narrow substrate
scope of strictosidine synthase, the enzyme at
the entry point of the pathway, limits a pathway
engineering approach. We demonstrate that
with a different expression system and screen-
ing method it is possible to rapidly identify stric-
tosidine synthase variants that accept trypt-
amine analogs not turned over by the wild-type
enzyme. The variants are used in stereoselec-
tive synthesis of b-carboline analogs and are
assessed for biosynthetic competence within
the terpene indole alkaloid pathway. These re-
sults present an opportunity to explore meta-
bolic engineering of ‘‘unnatural’’ product pro-
duction in the plant periwinkle.
INTRODUCTION
Monoterpene indole alkaloids (MIAs) from Catharanthus
roseus (Madagascar periwinkle) are structurally complex
natural products with well-established pharmacognosy
[1, 2]. The MIA biosynthetic pathway produces the antihy-
pertensive compound ajmalicine, 1; the topoisomerase II
inhibitor serpentine, 2; and the anticancer agents vinblas-
tine, 3, and vincristine, 4 (Figure 1) [1, 3, 4]. Interestingly,
derivatives of vinblastine such as Vinflunine (40-deoxy-
200,200-difluoro-C0-norvincaleukoblastine), 5, show excel-
lent anticancer activity in the clinic, indicating that small
changes to the alkaloid scaffold can improve or modulate
bioactivity (Figure 1) [5–7]. However, the current supply of
MIA analogs is primarily dependent on semisynthesis from
isolated pathway intermediates that are produced in low
yields.
Metabolic engineering of a biosynthetic pathway can
provide an efficient and environmentally friendly route to888 Chemistry & Biology 14, 888–897, August 2007 ª2007 Elnovel natural products or natural product derivatives. We
previously demonstrated that the MIA biosynthetic path-
way in C. roseus root cultures and seedlings can utilize
nonnatural substrates to synthesize an array of unnatural
MIA analogs [8]. However, the low substrate promiscuity
of the enzyme at the entry point in the pathway, stricto-
sidine synthase (STS), limits the scope of precursor-
directed biosynthesis efforts. STS catalyzes the stereose-
lective Pictet-Spengler reaction between tryptamine, 6a,
and secologanin, 7, to yield the tetrahydro-b-carboline
(3S)-strictosidine, 8a, as a single diastereomer (Figure 2)
[9]. Deglucosylation of 8a by the second enzyme of the
pathway, strictosidine glucosidase (SG), produces the
aglucone, 9, that is, in turn, enzymatically converted into
the structurally diverse group of MIAs produced in
C. roseus (Figure 2) [1, 2].
Reengineering STS substrate specificity is key for bio-
synthetic production of many MIA analogs. We recently
reported that a secologanin analog already accepted by
wild-type STS is selectively turned over by an STS mutant
(Asp177Ala) [10]. The observed switch in selectivity could
be rationalized based on the crystal structure of STS from
Rauvolfia serpentina in complex with secologanin (PDB ID:
2FPC) [11]. The efficiency of the rational redesign of en-
zyme active sites can often be improved by using satura-
tion mutagenesis protocols. However, the ineffectiveness
of current methods to assess STS activity limits this ‘‘ran-
dom’’ rational approach. Therefore, to rapidly obtain STS
mutants with expanded tryptamine specificity, we devel-
oped a streamlined expression system and colorimetric
assay for the Pictet-Spengler reaction. Herein, we de-
scribe the discovery of two STSmutants using this discov-
ery strategy that have broadened substrate specificity.
We highlight the potential applications of these mutants
in biosynthesis of unnatural alkaloid analogs.
RESULTS AND DISCUSSION
Development of a Colorimetric Assay
for STS Activity
The time-consuming high-performance liquid chromatog-
raphy (HPLC) assay used to measure catalytic activity
limits rapid reengineering of STS substrate specificity.
There are no reports of a high-throughput assay for Pic-
tet-Spengler activity. However, previous literature reports
noted that a yellow pigment forms after deglycosylation of
8a by SG [12, 13]. Inspired by these results, we developedsevier Ltd All rights reserved
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Enzyme Variants for Alkaloid BiosynthesisFigure 1. Structures of Selected Medicinal MIAs Produced or Derived from Madagascar Periwinkle, C. roseus
Ajmalicine, 1, acts as an antihypertensive agent; serpentine, 2, is a topoisomerase II inhibitor; vinblastine, 3, and vincristine, 4, are anticancer agents;
and Vinflunine, 5, is a modified vinblastine analog with promising bioactivity.an assay for visual detection of STS activity that could be
adapted to medium- or high-throughput screening.
In vitro deglycosylation by SG yields an equilibriummix-
ture of isomers of 4,21-dehydrogeissoschizine, 10, and
cathenamine, 11 (Figure 2) [14]. Previous literature sug-
gested that the yellow chromophore was a low-molecular
weight degradation product of 10 (dihydroflavopereirine)
[15]. However, liquid chromatography coupled to high-
resolution mass spectrometry (LC-HRMS) of yellow-col-
ored assay mixtures produced by us indicated the forma-
tion of compounds with m/z 493, 491, and 489 from the
initial deglycosylation products 10 and 11 (m/z 351). The
compound corresponding to m/z 493 disappeared after
overnight incubation to form compounds with m/z 491
and 489 exclusively.
It has been reported that deglycosylated 8a can form
amine adducts in the presence of excess ammonium sul-
fate, and that these adducts can further rearrange to form
a dihydropyridine ring, which can easily air oxidize to an
aromatic pyridine ring [16]. HRMS suggested that the
compounds in our assay corresponding to m/z 493, 491,
and 489 have molecular formulae consistent with trypt-
amine adducts of 10 in different oxidation states (see theChemistry & Biology 14, 88Supplemental Data available with this article online). Puri-
fication of the compounds corresponding to m/z 491 and
489 and analysis by 1D- and 2D-NMR suggested that the
tryptamine adducts formed in the assay undergo rear-
rangement and air oxidation, similar to what is reported
by Heinstein et al. [16] (Figure 2) (Supplemental Data).
The UV-VIS spectrum of the compound corresponding
to m/z 489 showed absorption maxima at 314 nm and
427 nm; m/z 491 had one unique absorption maximum
at 470 nm (data not shown).
If this assay is to be used for STS substrate reengineer-
ing, SG must accept analogs of 8a, and the resulting de-
glycosylated adducts must form the pigment. To deter-
mine the scope of the assay, we synthesized a variety of
strictosidine analogs (maleic acid buffer, 10 mM [pH 2])
to obtain a diastereomeric mixture of strictosidine analogs
that were then subjected to the assay conditions. Pigment
formation in the presence of excess tryptamine, 8a, or
tryptamine analogs yielded strictosidine, 8a, or stricto-
sidine analogs with substituents on the indole ring or
on the side chain (data not shown). Careful analysis
showed that the purified strictosidine analog 8m (m/z
561, 531+30) formed compounds corresponding to theFigure 2. STS-Catalyzed Formation of 8a via a Pictet-Spengler Reaction between 6a and 7
The reaction proceeds via an iminium intermediate, which undergoes electrophilic aromatic substitution and cyclization to give 8a. Deglucosylation by
a dedicated b-glucosidase forms an aglucone, 9, that rearranges into dehydrogeissochizine, 10, and cathenamine, 11. The deglucosylated products
are then enzymatically converted into the MIA structures observed in periwinkle. However, aglucone, 9, can be intercepted by amine nucleophiles to
form colored adducts.8–897, August 2007 ª2007 Elsevier Ltd All rights reserved 889
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Purification of C. roseus STS and Verifi-
cation of Mutagenesis and Screening
Methods
(A) Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) of STS samples.
STS has a calculated molecular weight of
37 kDa. Lane 1, relative mass marker. Lane
2, STS in media without FLAG tag. Lane 3,
STS in media with FLAG tag. Lane 4, anti-
FLAG antibody-purified STS from supernatant.
FLAG tag, Asp-Tyr-Lys-Asp4-Lys.
(B) Representative screen of STS activity after
randomization of a residue distant from the
active site (Tyr167). All wells contain the same assay mixture (2 mM 6a, 1 mM 7, SG, and 25 mM sodium phosphate buffer [pH 7.0]). The first column
contains no-insert and wild-type-insert controls (rows 1–4 and 5–8, respectively). Columns 2–10 (all rows) contain media from mutagenesis libraries.expected aglucone analogs 9m and 10m after deglycosy-
lation by SG (m/z 381, 351+30). Only after addition of ex-
cess tryptamine analog 6m to the deglycosylated prod-
ucts did the color form and the expected masses of the
analogous tryptamine adducts appear (m/z 553, 551,
and 549, M+60). Control assays lacking tryptamine or
a tryptamine analog did not form the putative adducts
and were not colored (Supplemental Data). Because of
the slow rate of chromophore formation relative to stricto-
sidine formation, this assay cannot be used as a quanti-
tative coupled assay of STS activity. Nevertheless, this
assay appeared to be a robust method for qualitative
detection of STS activity.
Expression System for Extracellular STS Activity
To facilitate screening for STS activity, we constructed
a plasmid that allows for export of STS to the media
upon expression in Saccharomyces cerevisiae. Although
the sts gene from C. roseus contains a putative native sig-
nal peptide (residues 1–26), expression in yeast did not re-
sult in significant protein export in S. cerevisiae. Replace-
ment of the nucleotides encoding the first 26 residues with
an N-terminal yeast mating-factor a signal sequence [17]
efficiently directed the export of STS to the culture media
(Figure 3A, lane 2). A C-terminal FLAG-peptide was also
introduced to allow for purification by affinity chromatog-
raphy (Figure 3A, lanes 3 and 4) [18].
Characterization of purified wild-type STS expressed
in yeast by a quantitative HPLC assay afforded kinetic
constants (Vmax = 21 U mg
1, KM = 1.4 mM; turnover
number assuming all enzyme is active: kcat = 78 min
1)
(Table 1). These values are consistent with constants re-
ported for STS purified from C. roseus (average of several
isoforms: Vmax = 14 U mg
1, KM = 9 mM) [19] and from
heterologously expressed STS from the medicinal plant
Rauvolfia serpentina (kcat = 78 min
1, KM = 6 mM, 88%
sequence similarity to C. roseus STS) [11]. Mutagenesis
studies of R. serpentina STS suggested that Glu309 is im-
portant for catalysis (Glu309 corresponds to Glu315 in the
C. roseus protein sequence) (Figure 4A) [11]. The >1000-
fold reduced turnover number of the analogous mutant
of C. roseus STS (Glu315Ala, Vmax = 0.012 U mg
1, KM =
0.44 mM) confirms this conclusion. When subjected to
the colorimetric assay conditions, Glu315Ala produced890 Chemistry & Biology 14, 888–897, August 2007 ª2007 Elsa faint yellow pigment (data not shown), suggesting that
this screen is sufficiently sensitive to detect weakly active
mutants.
Validation of Mutagenesis and Screening Strategy
The crystal structure of R. serpentina STS in complex with
tryptamine (PDB ID: 2FPB) was used to evaluate residues
involved in substrate binding and catalysis [11]. The rela-
tively high B factor of 6a in the crystal structure (3-fold
higher than the remainder of the protein) suggests that
6a may adopt a relatively flexible orientation in the active
site [11]. Moreover, the known substrate specificity of
STS cannot always be rationalized from the structural
data; for example, it is not clear why 5-hydroxytryptamine,
6f, is weakly turned over while 5-methyltryptamine, 6l, is
not. To expand our rational redesign approach, we used
saturation mutagenesis in combination with our screen
to probe all 20 naturally occurring amino acids at selected
residues in the tryptamine-binding pocket.
Codons were randomized by using primers containing
NNK/MNN degenerate codons (32 sequence possibili-
ties). To validate the mutagenesis strategy, expression
system, and screening method, a saturation mutagenesis
library of a tyrosine residue distant from the active site
(Tyr167Ala greatly reduces STS catalytic activity, unpub-
lished data) was constructed. The mutated gene and the
linearized expression vector were transformed into the
yeast expression host (S. cerevisiae BJ5465), and homol-
ogous recombination resulted in the production of the de-
sired STS variant library. Colonies were inoculated (88 per
mutated site, an oversampling that gives 94% certainty
that the library is complete [20]) into expression media in
deep-well, 96-well plates. The culture media were then
transferred to 96-well microtiter plates containing the
assay components 6a, 7, and SG. A positive control
from a yeast strain expressing wild-type and a negative
(empty-vector) control were included in the screen
(Figure 3B, column 1). Five clones that led to the formation
of a strong, yellow pigment were sequenced, and each
contained the wild-type gene. Cultures lacking pigment
yielded genes with a variety of mutations at tyrosine 167.
This test assay with the natural substrate 6a indicated
that the screen was robust enough to use to search for
STS variants with altered substrate specificity.evier Ltd All rights reserved
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and Residues for Mutagenesis
With the exception of Glu315, which is crucial for the ca-
talysis of the Pictet-Spengler reaction, the tryptamine-
binding site consists primarily of hydrophobic and aro-
matic residues, including Trp153, Tyr155, Val171, Val182,
Val214, and Phe232 (Figure 4A). Therefore, the pocket
may simply serve to foster tryptamine binding to the
enzyme in a productive orientation that promotes iminium
formation with the aldehyde substrate and cyclization to
form the tetrahydro-b-carboline. We hypothesized that
mutagenesis of residues in the tryptamine-binding pocket
will allow for productive binding and catalysis of sub-
strates not accepted by the wild-type enzyme.
We selected substrates for screening based onprevious
work on STS substrate specificity (Figure 4B). Tryptamine
analogs with amethyl substituent at the 4 or 7 position (6c,
6j) are accepted by the wild-type enzyme (11- and 27-fold
increased KM and 5- and 3-fold decreased kcat with 6c and
6j, respectively) [21]. Substitutions at the 5 and 6 positions
are less tolerated: although 5-hydroxytryptamine, 6f, and
6-methoxytryptamine, 6h, are weakly turned over by the
wild-type enzyme, 5-methyltryptamine, 6l, is not a sub-
strate. We selected 6l as a model compound to assaymu-
tants with increased tolerance to 5 indole substitutions.
The 20 position of the tryptamine side chain is also highly
sensitive toward substitution. A methyl group (racemic
starting material) is only weakly tolerated at the 20 position
[21]. We determined that (20R)-tryptophanol, 6m; (20S)-
tryptophanol, 6p; (20R)-tryptophan, 6q; (20S)-tryptophan,
6r; and (20R)-tryptophan methyl ester, 6s, are not ac-
cepted by the wild-type enzyme. Compounds 6m and
6p were selected for screening.
The intriguing limitation at the 5 position may be due to
the proximity of Val171 or Val214 (closest distances: 4.4 A˚
Table 1. Kinetic Constants for STS Variants Varying
Tryptamine 6a or an Analog of 6a
Variant,
Substrate
Vmax
(U mg1)a
KM
(mM)
Vmax/KM
(U mg1 mM1)a
Wild-type, 6a 21 0.0014 15,000
Glu315Ala, 6a 0.012 0.44 0.027
Val214Met, 6a 3.1 0.42 7.5
Val214Met, 6lb 0.051 0.37 0.14
Phe232Leu, 6a 0.24 0.62 0.39
Phe232Leu, 6mb 0.23 0.94 0.24
Kinetic assays were performed in 100 mM sodium phosphate
buffer (pH 7.0) using an internal standard (naphthyl acetic
acid), and samples were analyzed by HPLC for formation of
product. The error limit for kinetic assays is estimated at
20%. V and V/K parameters are obtained by nonlinear regres-
sion analysis by using the Northrop equation, and KM is
obtained from the Michaelis-Menten equation.
a 1 U = formation of 1 mmol product (8a or analog) per minute.
bCompounds 6l and 6m are not accepted by wild-type STS or
Glu315Ala STS.Chemistry & Biology 14, 88and 3.2 A˚, respectively). The 20 position is close to the
reactive amine, and large substituents at this position
may interfere with the catalytic machinery. In addition,
Phe232 could prevent reaction with tryptamine analogs
that have substitutions at the 20-proR hydrogen atom
(closest distance: 3.8 A˚), while Glu315 could prevent the
proS substitutions (3.3 A˚).
We anticipated that saturation mutagenesis of residues
Val171 or Val214 could help turnover of 6l, and mutagen-
esis of Phe232 or Glu315 would allow for reaction with 6m
and 6p (Figure 5). These four residues formed the basis for
our first efforts to alter the tryptamine substrate specificity
for STS.
Discovery of Active Mutants
The Val171, Val214, Phe232, or Glu315 libraries were ex-
pressed in 96-well plates. After protein expression, the
media containing the enzyme were transferred to micro-
titer plates for screening by using an assay solution con-
taining the appropriate analogs of 6a, as well as 7 and
SG. Color formation was detected visually after 24 hr of in-
cubation (Supplemental Data). The Val171 and Glu315 li-
braries did not produce positive hits toward 6l, 6m, or
6p (Figure 5). However, several members of the Val214 li-
brary showed activity toward 6l, as evidenced by the col-
orimetric assay. Interestingly, sequencing of three active
mutants revealed a Val214Met mutation. The methionine
substitution eliminates the side chain b branching that
could hinder reaction with 6l in wild-type STS. Since no
mutants containing smaller amino acids at Val214 were
isolated from the screen, we speculate that a longer side
chain is key for orienting the tryptamine analog optimally
for catalysis. (A differentR. serpentina STS variant that ac-
cepts 6lwas also found by J. Sto¨ckigt and coworkers, per-
sonal communication.) Further evaluation of this mutant
by LC-MS and HPLC showed that the Val214Met mutant
also accepts 5-chlorotryptamine, 6n, and 5-bromotrypt-
amine, 6o. Halogenated precursors are useful because
the distinctive isotopic signature allows for facile detection
of metabolites. Furthermore, aryl chlorides and bromides
can be used to derivatize pathway products via aromatic
crosscoupling reactions [22]. There is also some evidence
that bromination at this position in synthetic vinblastine
analogs has resulted in compounds displaying promising
antitumor activity [23].
The colorimetric assay also indicated that 6m was ac-
cepted by members of the Phe232 library (Figure 5). Se-
quencing of six active clones showed a substitution at res-
idue 232 to leucine (four of the six sequenced cultures) or
methionine (two of the six sequenced cultures). The 20-
proR hydrogen atom projects toward Phe232 (closest dis-
tance: 3.4 A˚), and mutagenesis of Phe232 to the smaller
leucine or methionine residue may help accommodate
the hydroxymethylene substituent. Initial experiments
with HPLC indicated that Phe232Leu was slightly more
active under the assay conditions; thus, the Phe232Leu
mutant was chosen for further characterization. Notably,
6p, 6r, and other tryptamine analogs with a substitution
at the 20-proS hydrogen are directed toward the catalytic8–897, August 2007 ª2007 Elsevier Ltd All rights reserved 891
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Enzyme Variants for Alkaloid BiosynthesisFigure 4. Tryptamine-Binding Site and Tryptamine Substrate Scope of STS
(A) Tryptamine-binding site of STS from R. serpentina (PDB ID: 2FPB, residues are numbered according to the C. roseus peptide sequence). Side
chains interacting with tryptamine are in stick representation. The protein main chain is represented in cartoon form.
(B) Tryptamine analogs with indole ring substitutions that are accepted by wild-type STS [21].Glu315 residue. Continued redesign of mutants that ac-
cept these substituents would likely be unwarranted, as
Glu315 is required for catalysis. Turnover of L-tryptophan,
6r, by STS could impact the cellular supply of tryptophan
and was likely subject to strong negative selection during
the evolution of STS.
Kinetic Analysis of STS Mutants
Larger-scale (500ml) expression of the enzymemutants in
yeast followed by purification of the concentrated media
with anti-FLAG antibody resin afforded Val214Met and
Phe232Leu in apparent homogeneity, as indicated by
SDS-PAGE (data not shown). Steady-state kinetic analy-
sis of Val214Met and Phe232Leu was performed with
both the natural substrate 6a and the substrate analogs
6l and 6m (Table 1). The mutants each have reduced892 Chemistry & Biology 14, 888–897, August 2007 ª2007 Elscatalytic capacity compared to the wild-type enzyme
(Vmax,wt/Vmax,mutant) using 6a (7-fold and 90-fold, respec-
tively). In addition to the 90-fold reduced Vmax, Phe232Leu
shows a >400-fold increasedMichaelis constant (Table 1).
This may be attributed to loss of the aromatic residue,
since phenylalanine may help orient the substrate cor-
rectly for catalysis or stabilize high-energy intermediates
in the reaction pathway. A comparison of the catalytic ef-
ficiency (Vmax/KM) of the mutants using 6a or the respec-
tive analogs of 6a suggested that both mutants are selec-
tive for tryptamine in the presence of the analog (50-fold
and 1.5-fold for Val214Met and Phe232Leu, respectively,
Table 1). Lowering the amount of 6a in cell culture by inhib-
iting tryptophan decarboxylase—the enzyme directly re-
sponsible for tryptamine biosynthesis—may be necessary
to suppress formation of native MIA analogs.Figure 5. Expanded Substrate Scope:
Tryptamine Analogs Assayed with STS
Variants Used in This Studyevier Ltd All rights reserved
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Analogs Formed by Feeding Strictosi-
dine Analogs to 2-Week-Old C. roseus
Hairy Root Cultures
(A) Formation of putative serpentine or a ser-
pentine isomer analog upon feeding of 8o to
periwinkle. The two top traces show that no
compounds corresponding to m/z 427 and
429 exist in the culture supplemented with
tryptamine, 6a. The bottom trace shows the
elution of an authentic standard of serpentine,
2. The remaining two traces show the forma-
tion of an alkaloid analog displaying the ex-
pected isotopic pattern that could be a bromi-
nated MIA analog.
(B) Formation of isositsirikine, 14m, in a feeding
study of 8m. The top trace shows the expected
mass of the alkaloid analog; the bottom trace
shows that no naturally occurring alkaloid of
m/z 385 coelutes with 14m.Preparative Enzymatic Synthesis of 8l–8n
and Characterization of Products
We used the Val214Met and Phe232Leu mutants in the
stereoselective preparative (mmol-scale) synthesis of
(3S)-strictosidine analogs 8l–8n. Although several chemi-
cal strategies for Pictet-Spengler reactions exist, forma-
tion of 8a in acidic aqueous media gave a low-yielding di-
astereomeric mixture of products (3R and 3S), as well as
numerous side products (data not shown). Expression of
the stsmutants in E. coli afforded crude cell extracts con-
taining either Val214Met or Phe232Leu. Despite the re-
duced Vmax of the mutants relative to wild-type enzyme
(Table 1), the extracts were conveniently used to synthe-
size 8l–8n on a mmol-scale. Gratifyingly, side products
were minimal, and the expected (3S)-diasteromer was
formed exclusively (d.r. > 99.5%). Preparative HPLC puri-
fication was used to separate the products from the un-
reacted starting materials. NMR and HRMS validated
the structures of the predicted strictosidine analogs (Ex-
perimental Procedures).
Biosynthetic Competence of StrictosidineAnalogs
We envision that Val214Met and Phe232Leu will be useful
for metabolic pathway engineering of alkaloid biosynthe-
sis. Previous reports demonstrate that MIA pathways
accept and process tryptamine and secologanin analogs
to form unnatural alkaloids [8, 10]. However, it is important
to validate whether the strictosidine analogs that are pro-
duced by STSmutants are in fact accepted by the remain-
der of the pathway.Chemistry & Biology 14, 888Decades of research on C. roseus plants and differenti-
ated cell cultures have yielded a wealth of structural and
biochemical information for the alkaloid profile, thereby fa-
cilitating analysis of the complex alkaloid production in C.
roseus [1]. LC-MS analysis of hairy root cultures supple-
mented with the natural substrate tryptamine 6a showed,
as expected, formation of the heteroyohimbine alkaloids
ajmalicine, 1 (m/z 353); serpentine, 2 (m/z 349); and yohim-
bine, 12 (m/z 355), as well as the more complex alkaloid
akuammacine, 13 (m/z 323) [8].
To assess the metabolic fate of tryptamine analogs that
are not accepted by the wild-type enzyme, the corre-
sponding strictosidine analogs have to be preformed
and then fed to the hairy root cell cultures. Reports in
the literature indicated that the relatively large strictosidine
biosynthetic intermediate could be taken up by plant cell
culture [24]. C. roseus hairy root cultures were supple-
mented with preformed 8m (product of Phe232Leu) and
8o (product of Val214Met) (Figure 5) at a final concentra-
tion of 0.5 mM, and the alkaloid content was extracted
from the media and the roots by using established proto-
cols [25]. Analysis of the media and the extracted cell cul-
tures by LC-MS suggested the presence of compounds
with masses corresponding to MIA analogs (with M+30
for alkaloids derived from 8m and M+78/80 for alkaloids
derived from 8o (Figure 6 and Supplemental Data). These
compounds were not observed in control cultures that
contained only the natural substrate tryptamine, 6a. Com-
pounds derived from 8o could be identified by the charac-
teristic isotopic distribution expected for brominated–897, August 2007 ª2007 Elsevier Ltd All rights reserved 893
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metabolites are derived from the halogenated strictosi-
dine precursor (Figure 6). Previous directed biosynthesis
experiments indicated that the MIA pathway tolerates
substituents on the indole ring [8]; thus, it was not surpris-
ing to see evidence for incorporation of 8o into products
with molecular masses corresponding to analogs of the
known MIAs 1, 2 (Figure 6A), 12, and 13 (Supplemental
Data).
For this study, we isolated and characterized an alkaloid
analog derived from 8m. A metabolite derived from 8m
was chosen because while tryptamine analogs with sub-
stituents on the indole ring have been previously shown
by rigorous structural characterization to be widely incor-
porated into the MIA pathway, the effect of a tryptamine
side chain substituent has not yet been explored. Further-
more, while alkaloids derived from 8o contain a unique
isotopic signature from the bromine atom, there is no dis-
tinctive isotopic signal for alkaloids derived from 8m. The
major product derived from 8mwas therefore purified and
characterized by NMR spectroscopy to validate the for-
mation of a terpene indole alkaloid analog.
Initial analysis of cultures supplemented with 8m by
LC-MS suggested the formation of an analog of a yohim-
bine-type alkaloid (m/z 385, 353+30, 14m) and an analog
of ajmalicine, 1, or an isomer of 1 (m/z 383, 353+30, 1m,
Supplemental Data). Additionally, an unknown analog
with m/z 426 (396+30), 15m, was formed (Supplemental
Data). The absence of m/z 379 in the media and extracts
suggests that the serpentine analog 2m cannot form
from 8m. This could be due to the absence of a (5-pro-
R)-hydrogen atom in the substrate, or the intracellular
localization of the biosynthetic intermediates may be al-
tered. A compound corresponding to the analog of the
more complex alkaloid 13 was also not observed, sug-
gesting that the (unknown) enzyme forming akuamma-
cine, 13, does not accept 8m as a precursor. Isolation,
cloning, and reengineering of these enzymes will be key
for studies relating to the biosynthesis of these analogs.
Interestingly, while the cell culture media did not appear
to contain any naturally occurring MIAs, analogs 14m
and 15m were present in the media. Although relatively
little is known about export mechanisms in plant cell cul-
ture, it is intriguing to speculate that the plant cell cultures
exported these products into the media [26].
Compounds 14m and 15m, found in both themedia and
in root extracts, appeared to be the major unnatural prod-
ucts. Preparative HPLC purification afforded 14m (2 mg,
3% yield) and 15m (1 mg, 1%) from 500 ml plant cell cul-
ture. Compound 15m proved intractable to structural as-
signment, as it was prone to decomposition and consisted
of several isomers that could not be separated. The obser-
vations of NMR signals for indole aromatic protons
strongly suggested assignment as an indole alkaloid (d
7.41 [d, 1H, J 7.7, H-9], 7.34 [d, 1H, J 8.2, H-12], 7.14 [t,
1H, J 7.6, H-10], 7.04 [t, 1H, J 7.5, H-11]), but no natural
alkaloid corresponding to either the proposed parent ion
m/z of 396 or the observed m/z 426 has been reported
from C. roseus. However, NMR analysis revealed that894 Chemistry & Biology 14, 888–897, August 2007 ª2007 Els14m is an analog of the MIA isositsirikine (Figure 6) [27,
28]. This compound was shown to have an unsubstituted
indole (7.5–7.1 ppm, 4H), an intact hydroxymethylene
group (4.0 and 3.8 ppm, 2H; compare to 4.0 and 3.8
ppm for 8m), and the methyl ester (s, 3.8 ppm, 3H). Also,
the spectrum revealed an ethylidene group containing
a trisubstituted alkene, since one olefinic hydrogen atom
appears as a quartet (6.0 ppm, J = 6.8 Hz) coupled to three
hydrogen atoms that appear as a doublet (1.9 ppm, J = 6.8
Hz). There are no reports on isolation of isositsirikine from
either roots or hairy root cultures of C. roseus, suggesting
that unusual biosynthetic precursors may form unex-
pected products [1].
Large-scale synthesis of the strictosidine analogs (600
Da) with the expensive secologanin substrate, 7, limits the
scope and rigor of these feeding studies. We anticipate
thatC. roseus cell lines expressing these STSmutants (us-
ing previously reported transformation methods [29]) will
have the capacity to synthesize the strictosidine analogs
from the more readily available tryptamine starting mate-
rials. More detailed analysis of the resulting alkaloid pro-
files by NMR spectroscopy would therefore be greatly fa-
cilitated. Construction of these transgenic cell lines is
currently underway.
SIGNIFICANCE
Modulating the substrate specificity of strictosidine
synthase (STS) is a critical step toward indole alkaloid
pathway engineering to yield nonnatural alkaloids. We
developed a streamlined method to expand the range
of substrate analogs accepted by STS. The expression
system and assay described here were used to iden-
tify two STS mutants that yield strictosidine analogs
that cannot be produced by the wild-type enzyme.
We anticipate that this assay can be applied to identify
additional mutants with alternate substrate specificity
or optimized selectivity. The assay may also facilitate
the identification of functional homologs of STS and
the introduction of STS activity in structurally related
enzymes. The Val214Met mutant allows for formation
of halogenated indole alkaloids, whichmay be derivat-
ized further by crosscoupling strategies. Inspection of
the isotopic pattern of crude cell lysates suggests that
a brominated strictosidine analog can be incorporated
into several alkaloidmetabolites ofC. roseus. STSmu-
tant Phe232Leu allows for formation of a strictosidine
analog with a modification at an aliphatic carbon.
Feeding studies of this strictosidine analog showed
that minor modifications to the side chain of trypt-
amine can cause major perturbations of the alkaloid
profile of C. roseus. These results represent a starting
point for investigations into how the STS variants can
interface with the later steps of the biosynthetic ma-
chinery. Future research will seek to understand how
these enzymemutants function in the context of trans-
genic Madagascar periwinkle cell lines.evier Ltd All rights reserved
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General Methods and Analytical Techniques
Secologanin was obtained by methanol extraction of Lonicera tatarica
as described previously [21]. Tryptamine and tryptamine analogs were
purchased in the highest available purity and were usedwithout further
purification. Protein was obtained as described below, and the protein
concentration was determined by measuring the absorbance at 280
nm (3 = 50,300 M1 cm1, http://www.expasy.ch/tools/protparam.
html). NMR spectra were acquired on Varian Inova 500 MHz or Bruker
600 MHz spectrometers.
LC-MS analysis was performed on a Waters LC-MS system. Com-
pounds were separated by an Acquity Ultra-Performance LC (UPLC)
BEH C18 column (1.7 mm, 2.1 3 100 mm) equipped in tandem with
an MS technologies Micromass LCT Premier with an electrospray ion-
ization (ESI) source and time-of-flight (TOF) detector. The chromato-
graphy solvent system consisted of acetonitrile/water (0.1% formic
acid). The capillary and sample cone voltages were 2000 V and 30 V,
respectively. The desolvation and source temperature were 350C
and 100C, respectively. The cone and desolvation gas flow rates
were 20 l/hr and 700 l/hr, respectively. High-resolution mass spectra
(HRMS) were obtained in accurate mass mode (W-mode) with reser-
pine (m/z 609.2812, as 1 nM solution, 40 ml/min) as reference. The
HPLC-based assay was carried out on a Beckman-Coulter System
Gold system equipped with a 125 solvent module, a 125 autosampler,
and a 168 detector. Data were processed (integrated) by using 32Karat
(v 7). A solvent system composed of acetonitrile/water (0.1% TFA)
was used with a reverse-phase column (HiBar RT 250-4, RP-select B,
5 mm).
Construction of Expression Vectors
The wild-type strictosidine synthase synthetic gene (sts) (with codon
usage optimized for expression in yeast) was amplified with PCR
primers that introduce sites for XhoI and HindIII (underlined) and the
FLAG tag epitope (italics): 50-CCGAAGCTTTCACCAATCTTGAAGA
AG-30, 50-CTCCTACGTTTCCTCCGGATCTGACTACAAGGATGACGA
CAACAAGTAGCTCGAGCGG-30. The primers were designed to elim-
inate the first 26 residues corresponding to a putative nativeN-terminal
signal sequence. The PCR fragment was subcloned into the pGEM-T
Easy Vector (Promega, Madison, WI) and then excised and ligated into
pGAL-MF (Dualsystems Biotech AG) to obtain pSTSMF-FLAG. The
hexahistidine-tagged protein expressed in E. coli was obtained by
PCR amplification of the sts gene in pSTSMF-FLAG by using primers
that introduce sites for NcoI and XhoI: 50-CATGCCATGGGCTCACCAA
TCTTGAAGAAGATC-30, 50-CCGCTCGAGGGAGGAAACGTAGGAGT
TTCCC-30; it was then ligated into pET-28a(+) to obtain pSTSMF-HIS.
Library Generation and Expression
Primers were designed to overlap with the plasmid sequence to allow
for homologous recombination in vivo. Degenerate codons (NNK/
MNN) reduced the library size by 2-fold as compared to complete ran-
domization (NNN/NNN). Two PCR reactions with the pSTSMF-FLAG
as a template afforded two sts gene fragments. Each fragment con-
tained a region of overlap (>20 bp) with the plasmid at one end and a
region of overlap with the other gene fragment (also containing themu-
tagenized codon) at the opposite end. This overlap allowed for the use
of homologous recombination to assemble the fragments into the sts
mutant in the desired plasmid. Digestion of the parental DNA and aga-
rose gel elecrophoresis purification was followed by a splicing-overlap
extension PCR reaction to assemble the mutated gene. Homologous
recombination of the mutated gene and digested pGAL-MF vector
created the saturation mutagenesis libraries. See the Supplemental
Data for more information.
Yeast colonies were inoculated in 300 ml SCMM-U (S. cerevisiae
minimal media, composition per liter: 6.7 g yeast extract without amino
acids and 1.92 g yeast supplemental media without uracil) supple-
mented with 2% glucose and incubated overnight at 30C in 96-well,
square-bottom, deep-well plates (2 ml volume capacity per well) withChemistry & Biology 14, 8shaking at 225 rpm. An aliquot of the overnight culture (100 ml) was
then used to inoculate 900 ml SCMM-U supplemented with 0.5% glu-
cose and 2% galactose and incubated for an additional 72–96 hr at
20C. Each well contained one glass bead (5 mm) to facilitate aeration,
and all plates were protected from contamination during the incubation
by sterile, breathable sealing film. The plates were centrifuged (10C,
3000 3 g, 10 min), and the supernatant was used directly for screen-
ing. We verified that the supernatant could be stored with cells at
4C for at least 4 weeks without noticeable loss of activity. 96-well
plates can be recultured in SCMM-U media or supplemented with
25% glycerol and stored at 80C for future use.
Kinetic Analysis of STS Variants
Reaction conditions weremodified to obtain less than 15%conversion
for all data points used in steady-state kinetic analysis. All enzymatic
reactions (0.100 ml) contained secologanin (4.0 mM) in sodium phos-
phate buffer (100 mM [pH 7.0]) with internal standard (0.075 mM naph-
thyl acetic acid) and one of several tryptamine or tryptamine analog
concentrations (always added as a 10-fold dilution from stock solu-
tion). Tryptamine or tryptamine analog concentrations were at least
2-fold above and below the estimated KM value. The HPLC detection
limit did not allow for substrate concentrations lower than 1 mM. For-
mation of strictosidine was monitored at 280 nm by using the experi-
mentally determined extinction coefficient of 5,140 mM1. Wild-type
reactions were quenched with two equivalents of sodium hydroxide
due to the fast reaction between tryptamine and secologanin. This
quench resulted in the quantitative formation of strictosamide
(C26H31N2O8 calculated: 499.2091, found: 499.2080) from strictosi-
dine, and the extinction coefficient of the strictosamide product was
experimentally determined to be 12,000 mM1. Plotted experimental
data were fitted to the Michaelis-Menten and Northrop equations by
nonlinear regression analysis by using Origin (v 7.0552) (OriginLab
Corp., Northampton, MA) to directly afford Vmax, Vmax/KM, and KM.
All kinetic assays were repeated three times to ensure reproducibility.
Representative raw data for the Val214Met mutant and 5-methyltrypt-
amine are shown in the Supplemental Data.
Feeding Study and Alkaloid Isolation
Hairy root cell cultures of C. roseus were inoculated in half-strength
Gamborg media and were grown for 3 weeks. Enzymatic synthesis
and purification afforded 8m (ESI-MS C28H36N2O10: calculated m/z
561.2448 [M+H]+, found m/z 561.2448 [M+H]+), and chemical syn-
thesis and purification afforded 8o (ESI-MS C27H34N2O9
79Br: calcu-
lated m/z 609.1448 [M+H]+, found m/z 609.1456 [M+H]+; ESI-MS
C27H34N2O9
81Br: calculatedm/z 611.1427 [M+H]+, found m/z 611.1453
[M+H]+). Each strictosidine analog was dissolved in water to a final
concentration of 0.5 mM, and the solution was filter sterilized and
then added to the hairy root culture. After 1 week, the media were
separated from the hairy roots, and the roots were washed with water
three times. The media and roots were extracted according to stan-
dard procedures (Supplemental Data) [25, 28]. The extracted alkaloids
were analyzed by LC-MS, and the two major species were isolated by
using preparative HPLC and were analyzed by NMR.
NMR Characterization of Enzymatically Generated
Strictosidine Analogs
(5R)-Hydroxymethylstrictosidine, 8m
1H NMR (methanol-d4, 500 MHz) d 7.80 (s, 1H, H-17), 7.46 (td, 1H,
3J10
7.8, 4J11 1.0, H-9), 7.33 (td, 1H,
3J11 8.2,
4J10 0.84, H-12), 7.15 (ddd, 1H,
3J10 7.1,
3J12 8.2,
4J9 1.1, H-11), 7.05 (ddd, 1H,
3J11 7.1,
3J9 8.2,
4J12
0.92, H-10), 5.84 (ddd, 1H 3J18trans 17.4,
3J18cis 10.6,
3J20 7.6, H-19),
5.80 (d, 1H, 3J20 8.8, H-21), 5.37 (ddd, 1H,
3J19 17.4,
2J18cis 1.3,
4J20
1.0, H-18trans), 5.28 (ddd, 1H, 3J19 10.6,
2J18trans 1.3,
4J20 1.0, H-
18cis), 4.78 (d, 1H, 3J20 7.9, GlcH-1
0), 4.67 (dd, 1H, 3J14proR 10.9,
3J14proS 4.0, H-3), 4.03 (dd, 1H,
3J23 10.7,
3J5a 3.4, H-23), 3.94 (dd,
1H, 2J60b 11.8,
3J50 2.1, GlcH-6
0a), 3.84–3.75 (m, 2H, H-5a, H-23),
3.78 (s, 3H, H-24), 3.62 (dd, 1H, 2J60a 11.9,
3J50 6.9, GlcH-6
0b), 3.40
(tapp, 1H,
3J20 ,40 9.1, GlcH-3
0), 3.36–3.32 (m, 1H, GlcH-50), 3.25–3.1988–897, August 2007 ª2007 Elsevier Ltd All rights reserved 895
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3J5a 4.8, H-6a), 3.04 (td, 1H,
3J14proS 11.2,
3J20,14proR 4.6, H-15), 2.89 (dd, 1H,
2J6a = 16.4,
3J5a 8.9,
H-6b), 2.77 (ddd, 1H, 3J15 5.0,
3J19 7.8,
3J21 8.6, H-20), 2.32 (ddd, 1H,
3J15 4.4,
3J3 11.1,
2J14proS 15.2, H-14proR), 2.24 (ddd, 1H,
3J3 4.2,
3J15
11.4, 2J14proR 15.2, H-14proS);
13C NMR (methanol-d4, 125 MHz)
d 171.28, 156.93, 138.45, 135.51, 130.46, 127.50, 123.79, 120.76,
120.08, 119.24, 112.48, 108.84, 106.25, 100.56, 97.54, 78.82, 78.08,
74.78, 71.82, 63.02, 62.03, 54.10, 52.76, 51.16, 45.34, 35.38, 32.63,
21.89; ESI-MS (C28H37N2O10
+): calculated m/z 561.2448 [M+H]+,
found m/z 561.2448 [M+H]+.
10-Methylstrictosidine, 8l
1H NMR (methanol-d4, 500 MHz) d 7.81 (s, 1H, H-17), 7.26 (s, 1H, H-9),
7.19 (d, 1H, 3J11 8.3, H-12), 6.98 (dd, 1H,
4J9 1.3,
3J12 8.4, H-11), 5.85
(ddd, 1H, 3J20 7.6,
3J18cis 10.6,
3J18trans 17.5, H-19), 5.84 (d, 1H,
3J20
9.1, H-21), 5.35 (dd, 1H, 2J18cis 1.3,
3J19 17.4, H-18trans), 5.28 (dd,
1H, 2J18trans 1.1,
3J19 10.6, H-18cis), 4.80 (d, 1H,
3J20 7.9, GlcH-1
0),
4.64 (br-d, 1H, 3J14proR,14proS 10.6, H-3), 3.98 (dd, 1H,
3J50 2.1,
2J60b
11.8, GlcH-60a), 3.80 (s, 3H, H-23), 3.73 (ddt, 1H, 3J50 5.0,
2J60a 12.5,
GlcH-60b), 3.49–3.42 (m, 1H, H-5a), 3.40 (tapp, 1H,
3J20 , 40 9.1, GlcH-
30 ), 3.39–3.35 (m, 1H, H-5b), 3.25–3.19 (m, 2H, GlcH-20, GlcH-40),
3.10–2.97 (m, 3H, H-6a, H-6b, H-15), 2.75 (ddd, 1H, 3J15 5.1,
3J19
7.8, 3J21 8.7, H-20), 2.40 (s, 3H, H-23), 3.36–2.16 (m, 2H, H-14proS,
H-14proR); 13C NMR (methanol-d4, 125 MHz) d 171.43, 157.05,
136.67, 135.62, 130.30, 130.03, 127.82, 125.24, 119.90, 118.91,
112.10, 109.08, 106.79, 100.56, 97.43, 78.96, 78.135, 74.80, 71.88,
63.15, 53.19, 52.74, 45.52, 42.80, 34.92, 32.75, 21.71, 19.71; ESI-
MS (C28H37N2O9
+): calculated m/z 545.2499 [M+H]+, found m/z
545.2523 [M+H]+.
10-Chlorostrictosidine, 8n
1H NMR (methanol-d4, 500 MHz) d 7.81 (s, 1H), 7.47 (dd, 1H,
5J12 0.6,
4J11 2.1, H-9), 7.29 (dd, 1H,
5J9 0.6,
3J12 8.7, H-12), 7.11 (dd, 1H,
4J9
2.0, 3J12 8.7, H-11), 5.85 (ddd, 1H,
3J20 7.7,
3J18trans 10.7,
3J18trans
17.4, H-19), 5.84 (d, 1H, 3J20 9.1, H-21), 5.35 (dtapp, 1H,
2J18cis 1.4,
4J20 1.4,
3J19 17.4, H-18trans), 5.28 (dtapp, 1H,
2J18trans 1.3,
4J20 1.3,
3J19 10.7, H-18cis), 4.80 (d, 1H,
3J20 7.9, H-1
0), 4.68 (br-d, 1H, 3J14proS,R
10.4, H-3), 3.98 (dd, 1H, 3J50 2.0,
2J60b 11.8, H-6
0a), 3.80 (s, 3H, H-23),
3.74 (td, 1H, 3J6ax,6eq 5.2,
2J5ax 12.5, H-5eq), 3.64 (dd, 1H,
3J5 7.1,
2J60a
11.8, H-60b), 3.47 (ddd, 1H, 3J6eq 5.6,
3J6ax 8.5,
2J5eq 12.5, H-5ax), 3.40
(tapp, 1H,
3J20 ,40 9.1, H-3
0), 3.39–3.34 (m, 1H, H-50), 3.23 (dd, 1H, 3J30 8.9,
3J50 9.9, H-4
0), 3.22 (dd, 1H, 3J10 7.9,
3J30 9.3, H-2
0), 3.13–3.05 (m, 2H, H-
6ax, H-15), 3.02 (tdapp, 1H,
3J5ax,5eq 4.5,
2J6ax 16.3, H-6eq), 2.75
(ddd(d), 1H, 4J18cis,trans < 0.5,
3J15 5.0,
3J19 7.8,
3J21 8.8, H-20), 2.32
(ddd, 1H, 3J3/15 3.0,
3J3/15 12.1,
2J14proS 15.0, H-14proR), 2.23 (ddd,
1H, 3J3/15 3.7,
3J3/15 11.8,
2J14proR 15.2, H-14proS);
13C NMR (metha-
nol-d4, 125 MHz) d 171.40, 157.06, 136.70, 135.54, 132.19, 128.65,
126.51, 123.80, 119.97, 118.84, 113.67, 109.03, 107.19, 100.54,
97.41, 78.95, 78.12, 74.79, 71.87, 63.15, 53.05, 52.74, 45.50, 42.63,
34.82, 32.68, 19.52; ESI-MS (C27H34N2O9
35Cl+): calculated m/z
[M+H]+ 565.1953, found m/z 565.1959; (C27H34N2O9
37Cl+): calculated
m/z [M+H]+ 567.1923, found m/z 567.1945.
NMR Characterization of Isositsirikine Alkaloid Analog, 14m
1H NMR (600 MHz, methanol-d4) d 7.51 (d, 1H,
3J10 7.7, H-9), 7.38 (d,
1H, 3J11 7.6, H-12), 7.26 (t, 1H,
3J9,11 7.6, H-10), 7.09 (t, 1H,
3J10,12 7.4,
H-11), 5.96 (q, 1H, 3J18 6.8, H-19), 4.94–4.87 (m, 1H, H-3), 4.20 (d, 1H,
2J21b 14, H-21a), 4.13 (d, 1H,
2J21a 14, H-21b), 4.04 (dd, 1H,
3J16 4.0,
2J17b 12, H-17a), 3.82 (dd, 1H,
3J16 4.7,
2J17a 12, H-17b), 3.99–3.85
(m, 2H, H-23a, H-23b), 3.76 (s, 3H, H-22), 3.67–3.58 (m, 1H, H-5),
3.20 (dd, 1H, 3J5 7.0,
2J6b 14, H-6a), 3.17–3.09 (m, 1H, H-16), 2.98
(dd, 1H, 3J5 7.0,
2J6a 15, H-6b), 2.87–2.82 (m, 1H, H-15), 2.59–2.42
(m, 2H, H-14), 1.87 (d, 3H, 3J19 6.8, H-18); ESI-MS (C22H29N2O4
+): cal-
culated m/z [M+H]+ 385.2127, found m/z 385.2134.
Supplemental Data
Supplemental Data include a detailed protocol for sts gene construc-
tion and expression, representative data for kinetic analysis, a protocol
for the generation of saturation mutation libraries, control experiments
for assay and MS and NMR data for chromophores, a protocol for en-
zyme screening in 96-well plates, protocols for enzymatic synthesis of896 Chemistry & Biology 14, 888–897, August 2007 ª2007 Elsevstrictosidine analogs, a detailed procedure for feeding studies, and
LC-MS data of feeding experiments and are available at http://www.
chembiol.com/cgi/content/full/14/8/888/DC1/.
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